glp-1 semaglutide and tirzepatide Ozempic® (semaglutide) Mounjaro™ (tirzepatide), a major breakthrough for the treatment of obesity Semaglutide vs Tirzepatide, which is

Conclusion: This meta-analysis demonstrates that GLP-1 receptor agonists are a promising therapeutic option for patients with IIH, demonstrating significant efficacy in reducing intracranial pressure-related symptoms such as BMI, headache frequency, papilledema, and visual disturbances

Belani A, Kresovi A, Troskot Dijan M (2021) Glucagon-like peptide-1 receptor agonists in the era of COVID -19: Friend or foe

GLP-1 and GIP, known as incretins, enhance insulin secretion in response to food intake, helping to lower blood glucose levels

As open enrollment periods approach and FSA deadlines loom in December, Ivm Health can help you navigate using your FSA/HSA benefits effectively for your weight management goals

Linda Chu, an obesity specialist